Table 6.
Summary of one-way sensitivity analysis results
| Parameter/scenario | ICER($perLYgained) for Oncotype DX testing versus usual care |
|
|---|---|---|
|
| ||
| −25% | +25% | |
| Base case | 5720.6 | |
| Cohort | ||
| Age | 5213.7 | 7971.7 |
| Cost | ||
| Cost of chemotherapy treatment | 5780.3 | 5661.0 |
| Cost of recurrence | 5725.5 | 5715.8 |
| Cost of Oncotype DX testing | 4226.2 | 7215.5 |
| Clinical parameters | ||
| Post-recurrence survival | 5705.1 | 5736.5 |
| Net change in the use of chemotherapy in the low Recurrence Score group | 8521.7 | 4330 |
| Net change in the use of chemotherapy in the intermediate Recurrence Score group | 5742.4 | 5699.6 |
| Net change in the use of chemotherapy in the high Recurrence Score group | 5836.8 | 4615.8 |
ICER: incremental cost-effectiveness ratio